Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $162.75 +0.70%
EPS Growth %: -5.5%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -5.5%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.88, $0.02 better than the analyst estimate of $1.86. Revenue for the quarter came in at $805.5 million versus the consensus estimate of $802.45 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.7-2.8 billion, versus the consensus of $3.41 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Varonis Said To Weigh Sale After Takeover Interest - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
